Jz. Ayanian et E. Guadagnoli, VARIATIONS IN BREAST-CANCER-TREATMENT BY PATIENT AND PROVIDER CHARACTERISTICS, Breast cancer research and treatment, 40(1), 1996, pp. 65-74
Guidelines for the optimal treatment of breast cancer have been public
ized over the past 15 years, yet clinical practices continue to vary s
ubstantially in the United States. This article reviews the literature
on variations in local and systemic treatment of breast cancer by pat
ient and provider characteristics. Studies of local therapy have consi
stently demonstrated that older women are less likely than younger wom
en to receive radiation therapy after breast-conserving surgery. Some
studies have noted that black women are less likely than white women t
o receive breast-conserving surgery and less likely to receive radiati
on therapy after breast-conserving surgery. Rates of breast-conserving
surgery vary three-fold among geographic regions and between teaching
and non-teaching hospitals. Patients at smaller hospitals appear less
likely to receive indicated radiation therapy. Patterns of systemic t
herapy have not been well described. Women over age 75 may not be rece
iving adequate hormonal therapy, but recent data are not available. Li
mited data suggest that rates of systemic therapy do not vary substant
ially by race or Hispanic ethnicity, but women without health insuranc
e may not be receiving appropriate chemotherapy. Studies relating hosp
ital and physician characteristics to the use of systemic therapy are
sparse and inconclusive. In order to increase the proportion of women
who receive optimal treatment for breast cancer and ensure greater equ
ity, a more sophisticated understanding of variations in clinical prac
tice will be required. These variations may arise from insufficient kn
owledge of or disagreement with guidelines among physicians, inadequat
e communication between physicians and patients, and individual prefer
ences or clinical attributes of patients. Future studies will need to
explore the dialogue between women and their physicians that leads to
decisions about treatment of breast cancer.